Cadrenal Therapeutics, Inc. Common Stock (CVKD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 555 | 0 | 401 | 0 | 5.52K | 0 | 0 | 0 | 0 | 0 | 0 | 597 | 0 | 760 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -555 | 0 | -401 | 0 | -5.52K | 0 | 0 | 0 | 0 | 0 | 0 | -597 | 0 | -760 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 89.94% | - | - | - | - | - | - | 100% | - | 100% | - | - | - | - | - |
| Operating Expenses | 2.51M | 3.07M | 2.73M | 3.73M | 3.92M | 4.28M | 2.46M | 2.47M | 1.76M | 1.26M | 1.14M | 1.03M | 4.2M | 1.08M | 972.79K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.74M | 2.4M | 2.04M | 2.66M | 2.25M | 2.74M | 1.67M | 1.21M | 1.13M | 902.11K | 898.05K | 784.62K | 964.73K | 958.83K | 915.9K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 771.51K | 666.32K | 688.47K | 1.08M | 1.67M | 1.54M | 784.65K | 1.25M | 629.02K | 361.13K | 243.95K | 240.96K | 3.24M | 116.38K | 56.39K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 555 | 555 | 401 | 401 | 0 | 407 | 407 | 470 | 597 | 597 | 597 | 597 | 190 | -506 | 506 |
| Operating Income | -2.51M | -3.07M | -2.73M | -3.73M | -3.93M | -4.28M | -2.46M | -2.47M | -1.76M | -1.26M | -1.14M | -1.03M | -4.2M | -1.08M | -972.79K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 35.99% | 28.36% | -11.13% | -51.39% | -123.74% | -238.53% | -115.3% | -140.37% | 58.2% | -17.46% | -17.46% | - | - | - | - |
| EBITDA | -2.51M | -3.06M | -2.73M | -3.73M | -3.92M | -4.28M | -2.46M | -2.47M | -1.76M | -1.26M | -1.14M | -1.03M | -4.2M | -1.08M | -972.28K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 35.91% | 28.37% | -11.13% | -51.41% | -123.5% | -238.66% | -115.37% | -140.46% | 58.21% | -17.49% | -17.46% | - | - | - | - |
| D&A (Non-Cash Add-back) | 555 | 555 | 401 | 401 | 5.52K | 407 | 407 | 470 | 597 | 597 | 597 | 597 | 190 | 760 | 506 |
| EBIT | -2.51M | -3.07M | -2.69M | -3.73M | -3.85M | -4.19M | -2.41M | -2.47M | -1.76M | -1.14M | -1.04M | -1M | -5.16M | -4.95M | -994.1K |
| Net Interest Income | 17.84K | 26.12K | 48.1K | 67K | 82.6K | 91.16K | 52.13K | 73.64K | 92.33K | 119.77K | 106.14K | 23.18K | -17.1K | -55.73K | -32.01K |
| Interest Income | 17.84K | 26.12K | 48.1K | 67K | 82.6K | 91.16K | 52.13K | 73.64K | 92.33K | 119.77K | 106.14K | 23.18K | 0 | - | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.1K | 55.73K | 32.01K |
| Other Income/Expense | 17.84K | 26.12K | 48.1K | 67K | 82.6K | 91.16K | 52.13K | 73.64K | 92.33K | 119.77K | 106.14K | 23.18K | -973.34K | -3.93M | -53.32K |
| Pretax Income | -2.5M | -3.04M | -2.69M | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.03M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.5M | -3.04M | -2.69M | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.03M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 35.08% | 27.42% | -11.54% | -53.25% | -131.19% | -266% | -132.31% | -138.58% | 67.85% | 77.16% | -1.01% | - | - | - | - |
| Net Income (Continuing) | -2.5M | -3.04M | -2.69M | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.04 | -1.41 | -1.31 | -1.87 | -2.09 | -2.75 | -2.18 | -2.24 | -1.55 | -1.32 | -1.19 | -1.28 | -6.62 | -6.46 | -0.09 |
| EPS Growth % | 50.24% | 48.73% | 39.91% | 16.52% | -34.84% | -108.33% | -83.19% | -75% | 76.59% | 79.57% | -1222.22% | - | - | - | - |
| EPS (Basic) | -1.04 | -1.41 | -1.31 | -1.87 | -2.09 | -2.75 | -2.18 | -2.24 | -1.55 | -1.32 | -1.19 | -1.28 | -6.62 | -6.46 | -0.09 |
| Diluted Shares Outstanding | 2.41M | 1.99M | 2.04M | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M |
| Basic Shares Outstanding | 2.41M | 1.99M | 2.04M | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |